By Ken Dropiewski Lipid-rich plaque in non-culprit lesions has long been associated with subsequent cardiac events. Unlike culprit lesions, known to be the cause of AMI, non-culprit lesions including those with a core of lipid-rich plaque are often left untreated during an intervention. The fact that these lesions may lead […]
Coronary/Structural Heart
Shockwave Medical Snags CE Mark for Coronary Lithoplasty System
FREMONT, Calif.–(BUSINESS WIRE)–Shockwave Medical, a pioneer in the treatment of calcified cardiovascular disease, today announced conformité européenne (CE) Mark for the company’s Coronary Lithoplasty® System for the treatment of calcified plaque in conjunction with stenting in patients with coronary artery disease. The Shockwave Medical Coronary Lithoplasty System is an innovative […]
NaviGate Cardiac Structures, Inc. (“NCSI”) reports first heterotopic transcatheter GATE™ tricuspid valved stent successful implantation
LAKE FOREST, Calif.–(BUSINESS WIRE)–NaviGate Cardiac Structures Inc. (“NCSI”) announced today that the GATE™ catheter-guided tricuspid atrioventricular valved stent (AVS) was implanted through the jugular vein one week ago in a patient suffering from severe tricuspid regurgitation stemming from two failed tricuspid annuloplasty rings that were unable to maintain the patient’s […]
Abiomed (ABMD) Introduces 3rd Generation Impella CP® Heart Pumps At SCAI 2017
DANVERS, Mass., May 09, 2017 (GLOBE NEWSWIRE) — Abiomed, Inc. (NASDAQ:ABMD), a leading provider of breakthrough heart support and recovery technologies, announced the debut of the 3rd Generation Impella CP heart pump at the Annual meeting of the Society for Cardiovascular and Angiography Interventions (SCAI 2017) in New Orleans, LA. […]
Daiichi Sankyo Initiates ENVISAGE-TAVI AF Study Investigating Once-Daily LIXIANA®▼ (edoxaban) in Patients with Atrial Fibrillation Undergoing Transcatheter Aortic Valve Implantation
MUNICH, April 27, 2017 /PRNewswire/ — ENVISAGE-TAVI AF is the first study to evaluate the effects of a novel oral anticoagulant on clinical outcomes exclusively in atrial fibrillation patients following successful transcatheter aortic valve implantation Study adds to the growing Edoxaban Clinical Research Programme (ECRP) evaluating its use in a […]
LivaNova (LIVN) Takes Out Caisson Interventional in $72 Million Deal
LONDON–(BUSINESS WIRE)–LivaNova PLC (NASDAQ:LIVN) (“LivaNova” or the “Company”), a market-leading medical technology company, today announced it has acquired the remaining outstanding interests in Caisson Interventional, LLC (“Caisson”), in support of LivaNova’s strategic growth initiatives. Based in Maple Grove, Minn., Caisson is a privately held clinical-stage medical device company focused on […]
Quanterix To Discuss Precision Cardiovascular Medicine At World Medical Innovation Forum
LEXINGTON, Mass.–(BUSINESS WIRE)–Quanterix Corporation, a company digitizing biomarker analysis to advance the science of precision health, today announced that Kevin Hrusovsky, CEO and Executive Chairman at Quanterix, will join a distinguished panel of industry experts to discuss the state and future of precision cardiovascular medicine at the World Medical Innovation […]
Medtronic Launches Resolute Onyx (TM) Drug-Eluting Stent in US Following FDA Approval Becoming First DES Available in 4.5mm and 5mm Sizes
By GlobeNewswire Engineered for Exceptional Deliverability, Advanced DES Technology Features Thinner Struts, Enhanced Visibility and the Broadest Size Matrix in the U.S. DUBLIN – May 1, 2017 -Medtronic plc (NYSE:MDT) today announced the U.S. Food and Drug Administration (FDA) approval and U.S. launch of the Resolute Onyx(TM) Drug-Eluting Stent (DES). […]
Venus Medtech’s TAVR Device Is Approved By CFDA, Creating A New Era Of Interventional Cardiology In China
HANGZHOU, China, April 28, 2017 /PRNewswire/ — Venus Medtech (Hangzhou) Inc., announced on April 25th that its transcatheter aortic valve system – Venus A-valve – has been approved by China Food and Drug Administration(“CFDA”) (registration no.: 20173460680) for sale in China. This marks the first-ever CFDA approved Transcatheter Aortic Valve Implantation […]
Fluctuations in Weight Leads to Dramatically Increased Risks for Cardiac Patients
By Ken Dropiewski Weight loss has always been suggested for those with a body mass index (BMI) over 30 in patients with cardiovascular disease as we know that obesity contributes to poor cardiac outcomes in that segment. However, a new study suggests that patients who experience a fluctuation in body […]


